Alaska Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Sanofi (OP: SNYNF)
109.09 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News
Press releases about Sanofi
 
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
May 21, 2013
Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils Read More
from PR Newswire
Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global Consolidation
May 21, 2013
from Business Wire News Releases
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
May 17, 2013
from PR Newswire
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
May 16, 2013
- Bettis Unveils New Playbook for Defending Against Severe Allergic Reactions and Urges Those Affected to Take Action - Read More
from PR Newswire
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
May 15, 2013
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials Read More
from PR Newswire
New Gold Bond® No Mess Powder Spray Introduced by Sanofi's Chattem
May 06, 2013
The same trusted formula in an easy aim spray Read More
from PR Newswire
Sanofi US and Actress Elizabeth Perkins Premiere Documentary -- Diabetes Co-Stars Presents "Strength in Numbers"
May 06, 2013
-Donation to Diabetes Hands Foundation Doubled When Documentary Reaches 10,000 Views- Read More
from PR Newswire
Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year
May 02, 2013
Growth platforms(2) sales increased 8.6%(3) Read More
from PR Newswire
Sanofi Q1 2013 - Interview with CFO Jérôme Contamine
May 02, 2013
from Business Wire News Releases
Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
April 25, 2013
from Business Wire News Releases
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
April 23, 2013
from PR Newswire
Genzyme Convenes 13th European Fabry Disease Roundtable
April 18, 2013
from Business Wire News Releases
New Allegra® Anti-Itch Cream Introduced by Sanofi's Chattem
April 11, 2013
Over-the-Counter Allergy Brand Now Offers Topical Relief for Itchy, Dry Skin Just in Time for Summer Read More
from PR Newswire
Pieris and Sanofi Broaden Existing Collaboration
April 10, 2013
from Business Wire News Releases
AUBAGIO® (teriflunomida) una vez al día por vía oral, de Genzyme, autorizado en Argentina para el tratamiento de la esclerosis múltiple recurrente
April 08, 2013
from Business Wire Spanish
Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis
April 08, 2013
from Business Wire News Releases
Basketball Legend Lisa Leslie Teams Up with Allegra® to Help Families Enjoy Outdoor Workouts This Allergy Season
March 28, 2013
Game On! Leslie and Sanofi's Chattem Encourage Families to Put Seasonal Allergies Behind Them and Stay Active This Spring Read More
from PR Newswire
Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments
March 25, 2013
from Business Wire News Releases
Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis
March 22, 2013
from Business Wire News Releases
Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies
March 21, 2013
from Business Wire News Releases
Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
March 14, 2013
- Sanofi US to Donate Up to $100,000 to Patient Organizations - Read More
from PR Newswire
Genzyme’s Multiple Sclerosis Franchise Featured at AAN
March 13, 2013
from Business Wire News Releases
Sanofi BioGENEius Challenge Canada celebrates 20 years of advancing science - 74% of SBCC participants pursued science careers thanks to national biotechnology research competition
March 07, 2013
from PR Newswire
Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
March 06, 2013
Cambridge, Massachusetts Mayor Signs Proclamation Declaring March 6 Colorectal Cancer Awareness Day Read More
from PR Newswire
Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation
March 04, 2013
from Business Wire News Releases
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
March 02, 2013
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology Read More
from PR Newswire
Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) Awards
February 28, 2013
from Business Wire News Releases
Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
February 27, 2013
from Business Wire News Releases
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
February 19, 2013
from PR Newswire
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease
February 15, 2013
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here